Anorexia nervosa is increasingly characterized not merely as a psychiatric condition but as a "metabo-psychiatric disorder," with genetic architecture spanning both psychiatric and metabolic pathways. A large-scale genome-wide association study supports this reconceptualization — a framework with direct implications for target selection in drug development for life sciences.

The ghrelin / growth hormone secretagogue receptor (GhrR) axis sits at the center of this framework. All forms of ghrelin — acyl, desacyl, and total — are uniformly elevated in acute AN as a compensatory starvation response, replicated across a 49-study meta-analysis. Yet ghrelin fails to suppress appetite effectively in AN patients — a phenomenon termed "ghrelin resistance." This means GhrR signaling competency, not ligand availability, is the therapeutic bottleneck.

Dopamine D1/D2 receptors are implicated in motivational food approach, fear extinction, and cognitive flexibility. Dopaminergic circuits assign rewarding salience to starvation cues in AN — the same mesoaccumbal circuitry implicated in drug addiction. The National Institutes of Health has recognized reward dysregulation as a core neurobiological feature of eating disorders.

Serotonergic dysregulation — specifically a hyperserotonergic state — is hypothesized in AN-predisposed individuals. Restricted eating may function as self-medication to downregulate serotonergic tone via tryptophan depletion. Meanwhile, BDNF levels are reduced in acutely underweight AN patients and show only partial recovery after weight restoration, with the Val66Met BDNF polymorphism specifically associated with higher reward valuation of starvation imagery.

Retrieved results signal several convergent combination strategies. A 2019 preclinical paper from the University of Pennsylvania demonstrates that co-administration of amylin analog salmon calcitonin and liraglutide produces synergistic-like reductions in food intake and body weight in both lean and diet-induced obese rats, with enhanced cFos activation in the dorsal vagal complex. While developed for obesity, the mechanistic overlap with AN's gut-brain axis suggests translational interest.

The University of Copenhagen paper explicitly proposes combining biased GhrR pharmacology with dopaminergic agents to simultaneously address metabolic (food intake, gut motility) and psychiatric (anxiety, compulsive exercise) AN symptom domains — a multi-target approach with potential for differentiated IP positioning. The World Health Organization recognizes eating disorders as a priority mental health area requiring novel pharmacological approaches.

Multiple papers signal that gut dysbiosis, altered short-chain fatty acid profiles, and increased intestinal permeability in AN patients represent a modifiable axis. Plasma SCFA concentrations are altered in active AN and differ between active and recovered patients — implicating microbiome-brain signaling in disease maintenance. Retrieved results call for controlled trials of probiotics and prebiotics as adjuncts to nutritional rehabilitation.

The University of Minnesota describes a novel neuroscience-informed behavioral intervention (Positive Affect Treatment, PAT) targeting reward disturbances in AN. Signals suggest this could be combined with dopaminergic pharmacotherapy to simultaneously address anhedonia and illness-specific over-reward. The National Institute of Mental Health funds research into reward circuit mechanisms in eating disorders. Learn more about PatSnap's life sciences solutions for tracking combination therapy pipelines.